Table 3 Comparison of characteristics at therapy cessation between sustained responder and recurrence
Characteristic | Sustained responder group | Recurrence group | P value |
|---|---|---|---|
Patients enrolled, n | 85 | 16 | |
Total PEG-IFN-α-2b injection (weeks) | 44.00 (24.00, 59.50) | 36.00 (21.00, 59.00) | 0.852 |
Treatment time (weeks) | 24.00 (13.50, 36.00) | 24.50 (15.75, 43.50) | 0.450 |
Received consolidative therapy, n (%) | 63 (74.12%) | 10 (62.50%) | 0.341 |
Consolidation time (weeks) | 12.00 (0.00, 24.00) | 6.00 (0.00, 12.00) | 0.116 |
Anti-HBs positive, n (%) | 55 (64.71%) | 4 (25.00%) | 0.003 |
Anti-HBs titer (mIU/ml) | 28.70 (0.00, 203.0) | 0.00 (0.00, 68.18) | 0.017 |
Blood routine test | |||
White blood cells (×109/L) | 2.84 (2.30, 3.44) | 3.21 (2.78, 3.92) | 0.116 |
Neutrophils (×109/L) | 1.49 (1.14, 1.79) | 1.62 (1.14, 2.30) | 0.618 |
Platelets (×109/L) | 114.5 ± 45.26 | 150.3 ± 57.87 | 0.007 |
Red blood cells (×1012/L) | 4.32 ± 0.58 | 4.26 ± 0.67 | 0.719 |
Hemoglobin (g/L) | 131.0 ± 18.67 | 129.1 ± 22.97 | 0.710 |
Liver function | |||
ALT (U/L) | 45.00 (29.50, 69.50) | 48.00 (25.50, 96.50) | 0.981 |
AST (U/L) | 45.00 (28.50, 70.00) | 40.00 (32.75, 82.00) | 0.996 |
T-BIL (µmol/L) | 13.50 (10.60, 17.00) | 12.30 (9.30, 16.58) | 0.421 |
Total protein (g/L) | 72.14 ± 3.89 | 74.11 ± 2.98 | 0.067 |
Albumin (g/L) | 45.85 ± 3.25 | 45.51 ± 3.75 | 0.714 |
Globulin (g/L) | 26.26 ± 3.72 | 28.58 ± 2.92 | 0.024 |